Skip to main content

Middle East Pharmaceutical Industries Company (4016.SR)

SAU Healthcare Medical - PharmaceuticalsView data quality →
60.8Fair

ValueMarkers Composite Index

Top 81%#8,550 of 44,714
Fairly Valued

5% above intrinsic value ($26)

UndervaluedFair ValueOvervalued
Piotroski
7/9
Strong
Beneish
-2.34
Low Risk
Altman
9.18
Safe
DCF Value
$26
Overvalued
ROIC
19.9%
Strong
P/E
21.3
Fair
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Middle East Pharmaceutical Industries Company (4016.SR) — VMCI valuation read

4016.SR screens at VMCI 61/100, a 11-point gap above the Healthcare sector median (50). For a mid-cap Middle East Pharmaceutical Industries Company share, that placement says the multi-pillar composite is cheaper or higher quality than the typical peer on a like-for-like basis.

4016.SR has logged no Form 4 insider activity over the trailing 30 days. The tape reads neither bullish nor bearish on insider conviction. The next signal sits with the 10-Q schedule and the analyst calendar.

**Investor frame.** Value: 4016.SR trades at 26.0x earnings, 44% above the Healthcare median of 18.0x, while EV/EBITDA prints 9.0x against 12.0x for the Healthcare group. Quality: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp, the cleanest like-for-like comparison on capital efficiency. Risk: net debt to EBITDA of 1.3x leaves covenant headroom, which sets the rate-cycle exposure for Middle East Pharmaceutical Industries Company.

4016.SR rose 1.9% over the trailing 7 days, with a -12.5% read on a 30-day basis.

Middle East Pharmaceutical Industries Company engages in the research, development, manufacture, and marketing of generic medicines and pharmaceutical preparations in the Kingdom of Saudi Arabia and internationally. The company operates through three segments: Private, Public, and Export. It offers medicines and preparations used to treat skin diseases, skin creams, and skin care products; respiratory, central nervous, digestive, and musculoskeletal system medicines; urinary and reproductive system drugs; disinfectants; and various therapeutic medicines and preparations, including sexual system drugs, diabetes, cardiovascular drugs, anti-infective drugs, anti-parasitic drugs, pain relievers, antiseptics, and women's and men's health drugs in the form of creams, rolls, ointments, syrups, masks, tonics, lotions, capsules, gels, hand sanitizers, mouthwashes, soaps, solutions, sprays, scrubs, topical solutions, and tablets. The company also provides contract manufacturing services. In addition, it specializes in cosmetic, health products and nutritional supplements. The company also exports its products. Middle East Pharmaceutical Industries Company was formerly known as Middle East Chemical Products Factory Company and changed its name to Middle East Pharmaceutical Industries Company in January 2006. Middle East Pharmaceutical Industries Company was incorporated in 1998 and is headquartered in Riyadh, the Kingdom of Saudi Arabia.

CEO: Mohammed Maher MohammedLotfi Al-Ghannam632 employeesSAwww.avalonpharmaceutical.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in 4016.SR’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.